The Swiss startup Aeon raises 8.2 million euros to prevent more than 500 diseases

The promise of effective, personalized and accessible medical prevention regularly returns to health innovation speeches. However, in fact, preventive medicine remains fragmented, not very predictive, and often marked by false positives or generic recommendations. It is precisely on this fault that Eon, a Swiss startup founded in 2023, intends to intervene. It has just raised 8.2 million euros in priming to deploy a technological platform that meets imaging, genetics and biological analyzes, with the ambition to transform prevention paths into concrete and measurable medical acts.

Installed in Zurich, Aeon combines three dimensions rarely combined in a routine check-up: Entire body, Analysis of advanced blood biomarkers and genetic tests. The whole is treated by an artificial owner intelligence architecture which allows both the detection of anomalies, the modeling of risk profiles and the drastic reduction of diagnostic errors. “” “We redefine health prevention by passing it from a reactive system to a proactive and personalized approach,”Explains Tim Seithe, founder and CEO of Aeon.“Each person receives a tailor -made risk profile, accompanied by a clear medical plan to monitor and reduce these risks over time.»

This approach contrasts with lighter market solutions, often centered on data from sensors or partial tests. AEON offers a complete evaluation in 60 minutes, validated by approved and contextualized doctors during an interview with a radiologist. This protocol would make it possible to detect and anticipate more than 500 pathologies, including early cancers, aneurysms or markers of neurodegenerative diseases.

The use of AI is not based solely on image analysis. AEON claims three complementary uses, the automated detection of MRI anomalies, the cross correlation of data from biological and genetic examinations, and the generation of a personalized predictive model. One of the major issues remains the fight against false positives. “” “This is one of the historical challenges of preventive medicine. An examination must alert without overding. To date, we have maintained a 0 % false rate in clinical follow -ups”Indicates the startup.

In a context marked by the rise of chronic diseases, more than 41 million deaths per year according to the WHO, 80 % of which would be avoidable, the promises of preventive medicine are regularly highlighted. However, existing models are struggling to reconcile medical relevance, financial accessibility and clinical rigor. In the United States, companies like Prenévo Or Q organic Popularized preventive MRIs and digital health modeling, but their access remains reserved for affluent customers and their low -integrated methods in reimbursed care systems.

More recently, new entrants have emerged with strong technological ambitions. In Sweden, Neko Healthco-founded by Daniel Ek (Spotify), offers a check-up in 10 minutes using optical and body scanners. The experience is fluid, the automated analysis, but the service is not based on MRI or genetic data. The model remains limited to diagnostics with little clinical integration. In France, Zoi Develops a concept of prevention centers combining organic examinations, health interviews and personalized recommendations. The promise is oriented towards accessibility, but is not yet based on complex medical devices or a multimodal AI.

In France, the market remains dominated by punctual check-ups in private clinics, often not covered by mutuals, and by occupational medicine with predictive technological tools. No French startup today offers an approach combining MRI, biomarkers and genetic sequencing in a unified and medically validated course.

On the other hand, some French players invest the field of prevention from another angle. Alanfor example, has built a health monitoring platform integrated into its insurance offer, combining teleconsultation, digital routes (sleep, nutrition, stress) and personalized advice. The approach is based on everyday life and therapeutic education, without heavy medical acts. Where Alan acts like a health guideAeon positions himself as a advanced and clinically validated screening tool. The two visions can coexist: one upstream, on the ground of well-being and behavior; the other downstream, on early detection and medical decision.

The model already interests several Swiss insurers, starting with Kptwhich proposes to reimburse up to 80 % of the cost of the exam depending on the contract subscribed. A stage deemed crucial by the rounding investors, led by the London Fund Concentric, with the participation of Calm/Storm Ventures, Gohub Ventures, Kadmos Capital, EWOR, and the Swiss investor Daniel Gutenberg. “Aeon is not yet another test solution. The majority of consumer health products have questionable medical value. Here, we have a clinically validated platform and reimbursed by insurers. It is a rare alignment between scientific rigor and commercial scalability,” comments Alex Stroud, principal at Concentric.

The funding obtained will allow Aeon to strengthen its presence in Switzerland and to deploy in Germany and the United Kingdom. More than ten new centers are planned in the coming months. The company also works to expand its partnerships with employers and health insurance, while continuing to enrich its technological platform.

The founding team brings together Tim Seithe, former founder of Tillhub (sold to Unzer, KKR group), and Samuel Frey, ex-responsible product at Platomics. The scientific committee includes Dr. Andreas Lemke, MRI specialist and founder of Mediaire, an active company in the brain diagnosis assisted by IA.